Maelia Uy-Gomez, a field application scientist at Astrea Bioseparations, will host a live webinar on September 17, 2026, to address these technical bottlenecks. The session shifts the industry focus away from standard platform strategies toward outcome-led purification, emphasizing selective capture and multimodal chromatography techniques.
Refining Downstream Processing for Complex Bispecific Biologics
As bispecific antibodies move from clinical pipelines toward commercial manufacturing, traditional monoclonal antibody platforms are failing to resolve complex impurity profiles. Downstream teams now face the critical challenge of balancing high-molecular-weight aggregates and host cell proteins with the need for scalable, efficient purification processes.
By prioritizing process-specific requirements over rigid platform models, developers can better manage impurities that standard chromatography screens often miss. The presentation includes case studies on Fc and non-Fc antibody capture, as well as targeted host cell protein polishing, aimed at building confidence before scaling production. Attendees will gain insight into how these differentiated separation mechanisms support more purposeful downstream development when working with limited clinical material.
Comments (0)
No comments yet. Be the first!